{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:49:29Z","timestamp":1776253769665,"version":"3.50.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,15]]},"DOI":"10.7759\/cureus.107078","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T10:54:54Z","timestamp":1776250494000},"source":"Crossref","is-referenced-by-count":0,"title":["Exceptional Response to Pembrolizumab Immunotherapy in a Young Patient With Lynch Syndrome-Associated Metastatic Colorectal Cancer"],"prefix":"10.7759","author":[{"given":"Muhammad","family":"Niazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Crossley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Stage IV colorectal cancer","author":"Rodriguez-Bigas MA","year":"2003","unstructured":"Rodriguez-Bigas MA, Lin EH, Crane CH. Stage IV colorectal cancer. Holland-Frei Cancer Medicine. 6th edition. Kufe DW, Pollock RE, Weichselbaum RR, et al. (ed): BC Decker, Hamilton (ON); 2003."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2010.0006","article-title":"Risk assessment, genetic testing, and management of Lynch syndrome","volume":"8","author":"Grover S","year":"2010","unstructured":"Grover S, Syngal S. Risk assessment, genetic testing, and management of Lynch syndrome. J Natl Compr Canc Netw. 2010, 8:98-105. 10.6004\/jnccn.2010.0006","journal-title":"J Natl Compr Canc Netw"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9 T","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, et al.. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020, 383:2207-18. 10.1056\/NEJMoa2017699","journal-title":"N Engl J Med"},{"key":"ref4","unstructured":"Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care. (2023). Accessed. March 15, 2026: https:\/\/www.nice.org.uk\/guidance\/htg690."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"de Filette J","year":"2016","unstructured":"de Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B, Neyns B, Bravenboer B. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab. 2016, 101:4431-9. 10.1210\/jc.2016-2300","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30366-4","article-title":"Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial","volume":"395","author":"Burn J","year":"2020","unstructured":"Burn J, Sheth H, Elliott F, et al.. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet. 2020, 395:1855-63. 10.1016\/S0140-6736(20)30366-4","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andr\u00e9 T","year":"2025","unstructured":"Andr\u00e9 T, Elez E, Lenz HJ, et al.. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet. 2025, 405:383-95. 10.1016\/S0140-6736(24)02848-4","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/474815-exceptional-response-to-pembrolizumab-immunotherapy-in-a-young-patient-with-lynch-syndrome-associated-metastatic-colorectal-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T10:54:56Z","timestamp":1776250496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/474815-exceptional-response-to-pembrolizumab-immunotherapy-in-a-young-patient-with-lynch-syndrome-associated-metastatic-colorectal-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.107078","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,15]]}}}